RESNICK NEUROPSYCHIATRIC HOSPITAL AT
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $78.3M
- Transactions
- 4,844
- Companies
- 40
- Average per transaction
- $16,172
Who reported the payments
| Pfizer | $12,466,477 |
| Genentech, Inc. | $10,769,041 |
| Novartis | $6,534,753 |
| Gilead | $5,901,226 |
| E.r. Squibb & Sons, L.L.C. | $5,020,544 |
| Janssen Research & Development, LLC | $3,480,498 |
| Servier Bioinnovation | $3,342,917 |
| AbbVie | $2,730,088 |
| CSL Behring | $2,526,222 |
| Modernatx, Inc. | $2,525,654 |
| Seagen Inc. | $2,464,231 |
| Bristol Myers Squibb | $1,451,824 |
| Genmab A/s | $1,412,928 |
| Sanofi | $1,408,497 |
| Edwards Lifesciences | $1,381,558 |
| Amgen | $891,734 |
| Siemens Medical Solutions USA, Inc. | $828,034 |
| Regeneron | $788,583 |
| Boehringer Ingelheim | $650,733 |
| Array Biopharma Inc | $639,666 |
| Varian Medical Systems, Inc. | $622,342 |
| Sanofi US Services Inc. | $619,000 |
| Hoffmann-la Roche Limited | $585,544 |
| Incyte Corporation | $561,726 |
| F. Hoffmann-la Roche AG | $509,254 |
| Stemline Therapeutics Inc. | $501,952 |
| Roche Products Limited | $489,438 |
| Puma Biotechnology, Inc. | $481,041 |
| Endo Pharmaceuticals Inc. | $457,912 |
| Daiichi Sankyo Inc. | $447,996 |
| Actelion Pharmaceuticals US, Inc. | $401,767 |
| Exelixis Inc. | $352,449 |
| Bayer | $253,460 |
| Medical Device Business Services, Inc. | $222,017 |
| Diasorin Molecular LLC | $217,073 |
| Karyopharm Therapeutics Inc. | $212,244 |
| Align Technology, Inc. | $199,920 |
| Zimmer Biomet | $198,984 |
| AstraZeneca | $180,657 |
| Immunogen, Inc. | $174,955 |